Tempus AI, Inc. × Ambry Genetics
Tempus AI announced the completion of its acquisition of Ambry Genetics on February 3, 2025. [45, 66] The total consideration was $600 million, paid as $375 million in cash and $225 million in Tempus shares. [45, 57] The acquisition combines Ambry's extensive genetic testing services with Tempus's AI and data platform to advance precision medicine. [54, 57]
The asset
A recognized leader in genetic testing, providing Tempus with expanded diagnostic capabilities and a large library of genomic data. [45, 54]
The record
- Seller status
- Going concern
- Sector
- Genetic diagnostics and testing
- Modalities
- genomic, clinical
- Jurisdiction
- US
- Personal data
- Ambry Genetics' mission involves translating scientific research into clinically actionable test results, a process governed by health privacy regulations. [117] Data is used for research to understand the relationship between genetics and disease. [45]
What it means if you hold data
This transaction demonstrates a key strategy in precision medicine: vertically integrating diagnostic testing with AI-driven data analysis. By acquiring the source of the genomic data, Tempus enhances its ability to build and refine its multimodal data library, which is the core engine for its research and clinical offerings. [67]